GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Float Percentage Of Total Shares Outstanding

AIM ImmunoTech (STU:HXB2) Float Percentage Of Total Shares Outstanding : 96.79% (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AIM ImmunoTech's float shares is 49.64 Mil. AIM ImmunoTech's total shares outstanding is 51.28 Mil. AIM ImmunoTech's float percentage of total shares outstanding is 96.79%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AIM ImmunoTech's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AIM ImmunoTech's Institutional Ownership is 6.78%.

AIM ImmunoTech Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

AIM ImmunoTech's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=49.64/51.28
=96.79%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech (STU:HXB2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
SYBX LSTA NRXS NRSN TCRT BIOR BIXT LUMO ZIVO CNTX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
AIM:USA HXB2:Germany
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
Website
https://www.aimimmuno.com
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines